<DOC>
	<DOC>NCT02294552</DOC>
	<brief_summary>This study evaluates the efficacy of high-dose post-transplantation cyclophosphomide as graft-versus-host disease (GVHD) prophylaxis after allogeneic stem cell transplantation in patients with different risk of GVHD. The risk-adapted strategy involves using single-agent cyclophosphomide in recipients of matched bone marrow graft, and combining cyclophosphomide with tacrolimus and mycophenolate mofetil in recipients of matched peripheral blood stem cells and mismatched bone marrow.</brief_summary>
	<brief_title>Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Immune System Diseases</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Antineoplastic Agents, Alkylating</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients must have an indication for allogeneic hematopoietic stem cell transplantation Signed informed consent Patients with a donor available. The donor and recipient must be identical at at least one allele of each of the following genetic loci: HLAA, HLAB, HLACw, HLADRB1, and HLADQB1. A minimum match of 5/10 is required for related donor. A minimum match of 8/10 is required for unrelated donor. No second tumors No severe concurrent illness Moderate or severe cardiac dysfunction, left ventricular ejection fraction &lt;50% Moderate or severe decrease in pulmonary function, FEV1 &lt;70% or DLCO&lt;70% of predicted Respiratory distress &gt;grade I Severe organ dysfunction: AST or ALT &gt;5 upper normal limits, bilirubin &gt;1.5 upper normal limits, creatinine &gt;2 upper normal limits Creatinine clearance &lt; 60 mL/min Uncontrolled bacterial or fungal infection at the time of enrollment Requirement for vasopressor support at the time of enrollment Karnofsky index &lt;30% Pregnancy Somatic or psychiatric disorder making the patient unable to sign informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Immunosuppressive Agents</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Mycophenolate mofetil</keyword>
	<keyword>Antineoplastic Agents, Alkylating</keyword>
	<keyword>Myeloablative Agonists</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>Allogeneic</keyword>
</DOC>